Navigation Links
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Date:10/17/2011

orical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the timing, scope and outcomes of our clinical trials as well as expected activities under our collaborative partnerships) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including clinical trial enrollment and results, regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact
Kurt Gustafson
Chief Financial Officer
(858) 704-8272
kgustafson@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  The International Trade Commission (ITC) issued ... against BMC Medical. In a notice issued on December 23, ... ResMed,s patent on its humidifier was invalid. BMC ... win". "We are very excited with the ITC,s decision in ... we have taken since the very beginning on the key ...
(Date:12/24/2014)... SCHOFIELD, Wis. , Dec. 23, 2014 ... and marketer of over-the-counter (OTC) medicinal and healthcare products, ... production of MigraPure® H, a hemp-based, advanced headache relief ... marijuana dispensaries in Colorado , ... . With the MigraPure H Advanced ...
(Date:12/24/2014)... 23, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today announced ... the Marketing Authorization Application (MAA) for sebelipase alfa ... company,s request for accelerated assessment, which has the ... The MAA, and the Biologics ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
(Date:12/25/2014)... December 25, 2014 Each year trauma ... 2 million hospital admissions across the nation (according to ... The CDC’s National Hospital Ambulatory Medical Care Survey ... survey conducted in 2010. They estimated that there were ... resulted in a primary diagnosis of broken bone or ...
(Date:12/24/2014)... December 24, 2014 Connie Casad, MD, ... functional medicine advocate with 30 years of practice experience ... evaluate the health benefits of dietary detoxification. The second ... participants following excellent results from test patients who just ... to explain her interest in conducting the study, Dr. ...
(Date:12/24/2014)... New York (PRWEB) December 24, 2014 ... http://www.xareltolawsuit2015.com/ ) that allege the blood thinner caused ... has outlined a leadership structure for the proceeding, ... dated December 17th, the Court plans to select ... parties and also plans on appointing a Plaintiffs’ ...
(Date:12/24/2014)... 25, 2014 BambooIndustry.com a famous bamboo ... years. Today, the company announces its multiple layer ... offer on these new products. , Bamboo panel is ... The multiple layer bamboo panel board features high quality ... and emissions free. The bamboo panel consists of multiple ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Adults who ... risk of migraine headaches, suggests a study published ... . "Childhood maltreatment can have long-lasting effects, ... in adulthood," study author Dawn Buse, director of ... York City, said in a journal news release. ...
Breaking Medicine News(10 mins):Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2
... shot, study finds , , TUESDAY, March 24 (HealthDay News) -- ... the 1980s and 1990s contained DNA from human papillomavirus type ... study. , It also found that women diagnosed with HPV16- ... than those diagnosed with cancers associated with other HPV types. ...
... Human Cytomegalovirus Stimulates Telomerase Activity in Tissue Culture ... triggers expression of the telomerase reverse transcriptase (hTERT) ... cells grown in culture. , HCMV has been ... mechanism by which the virus acts has been ...
... 24 Dr. Janet Neigel and the staff at the ... much-anticipated May 3rd, Pre-Mother,s Day Open House. The Center, located ... Jersey, will open its doors on May 3rd, 2009 between ... healthy solutions to their various cosmetic needs. The Pre-Mother,s Day ...
... ate higher amounts of soy during childhood had a 58 ... published in Cancer Epidemiology, Biomarkers and Prevention , a ... breast cancer incidence rates have been four to seven times ... in China or Japan. However, when Asian women migrate to ...
... about the threat of tuberculosis and the toll it takes ... Day. , The TB-HIV co-infection crisis is twice as ... 2007, there were at least 1.37 million cases of HIV-positive ... double the previous WHO estimates. , "A global health ...
... Clinical Specialists to Present Clinical Experience at American Burn ... Nephew Inc,s Advanced Wound Management division (LSE: SN; NYSE: ... titled "Optimizing Outcomes in Burn Care" at the 41st ... this symposium, top burn specialists will present their clinical ...
Cached Medicine News:Health News:HPV Data May Aid Vaccine's Effectiveness 2Health News:Also in the March 24 JNCI 2Health News:Also in the March 24 JNCI 3Health News:Also in the March 24 JNCI 4Health News:Also in the March 24 JNCI 5Health News:Also in the March 24 JNCI 6Health News:Spring Forward with a New You! The Neigel Center for Cosmetic and Laser Surgery Hosts Its May 3rd Pre-Mother's Day Open House! 2Health News:Eating soy early in life may reduce breast cancer among Asian women 2Health News:Alarming new data shows TB-HIV co-infection a bigger threat 2Health News:Smith & Nephew Announces Symposium for Optimizing Outcomes in Burn Care 2Health News:Smith & Nephew Announces Symposium for Optimizing Outcomes in Burn Care 3Health News:Smith & Nephew Announces Symposium for Optimizing Outcomes in Burn Care 4
The Bledsoe Basic Knee Brace offers a broad range of features that are unmatched by any other brace in its price range. Application of this brace is the easiest of any brace on the market....
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
SofTec Genu is the first functional brace that provides full soft tissue control, enhances natural muscle movement, prevents atrophy, increases proprioception and controls A/P laxity....
McDavid® Patella Knee Support helps relieve the symptoms of chondromalacia patellar subluxation and patellar tendonitis. Features two medial and two lateral spring-steel stays. 3/16" thick neopre...
Medicine Products: